The vaccine, developed by NantCell and NantKwest, is the first combination immunotherapy protocol that orchestrates the delivery of metronomic low-dose radiation and chemotherapy with molecularly informed tumor-associated antigen vaccines and off-the-shelf “natural killer” (NK) cells. Read more . . .
The U.S. Food and Drug Administration (FDA) has granted investigational new drug status to the NANT cancer vaccine, to be assessed in a Phase 1/2 clinical trial (NCT03136406) for pancreatic cancer patients who progressed during or following standard-of care therapy.